Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

Fig. 1

Platelet VEGF levels in healthy individuals and cancer patients analyzed by gender distribution. a Platelet VEGF levels in healthy women and healthy men. b Platelet VEGF levels before vaccination (week 0) in cancer patients recruited for CENTAURO and CENTAURO-2 clinical trials. c Platelet VEGF levels after vaccination (week 13) in cancer patients recruited for CENTAURO and CENTAURO-2 clinical trials. Horizontal bars represent the median values of platelet VEGF. ns non-significant

Back to article page